ReviewChembiochem : a European journal of chemical biology2026
Contrast Agents for Enhanced Bioimaging: A Comprehensive Review.
Review in Chembiochem : a European journal of chemical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Nanotechnology has significantly boosted analytical methods capable of visualizing and characterizing materials at the nanoscale, enabling disease monitoring with high precision. These advances have become particularly relevant in biomedical research, where the demand for enhanced diagnostic tools continues to grow. In this context, contrast agents (CAs) have emerged as essential components in modern imaging techniques, driving efforts toward the development of safer, more efficient, and selective diagnostic materials. The growth in the development of CAs reflects the expansion of applications in imaging modalities. Treatment techniques have benefited from nanotechnology innovations in recent decades, while advancements in imaging modalities demonstrate the demand for next-generation CAs with enhanced resolution and sensitivity. Nanomaterials play a central role in this progress, offering high surface area, adjustable porosity, structural stability, and easy functionalization, for drug delivery and disease monitoring. Hybrid nanoparticles, including core-shell systems, clustered architectures, and nanocomposites integrating metallic or magnetic materials with mesoporous silica, zeolites, or metal-organic frameworks (MOFs), allow control of magnetic relaxivity, X-ray attenuation, optical response, and biological interactions. Molecular scale and nanosized materials contribute to improved contrast, targeted delivery, and enhanced biocompatibility in bioimaging. Together, these advances highlight the potential of nanotechnology to transform biomedical diagnostics and disease detection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.